We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
3 Reasons Why You Should Invest in Edwards Lifesciences Now
Read MoreHide Full Article
Edwards Lifesciences Corporation (EW - Free Report) has been on a healthy growth trajectory of late. Positive tidings on the regulatory front have been lending the company a competitive edge in MedTech. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
Edwards Lifesciences has outperformed the broader industry over the last three months. The stock has gained 19.6%, ahead of the S&P 500’s decline of 3.8% and the industry’s 5.2%.
The stock has a market cap of $24.19 billion. The company’s five-year historical growth rate is also favorable at 23.4% compared with the 10.2% increase of its industry and the S&P 500’s 2.8% gain.
The company has a positive earnings surprise of 9.9% for the last four quarters. Also, it has a long-term expected earnings growth rate of 15.1%.
Headquartered in Irvine, CA, the company’s estimate revision trend for the current year has been positive. In the past couple of months, 12 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 8.7% to $4.52 per share over the same time frame.
Let’s find out whether the recent positive trend is a sustainable one.
Favorable Regulatory Tidings
In a bid to strengthen its position in predictive analytics, Edwards Lifesciences recently announced the approval of De Novo request from the FDA for the Acumen Hypotension Prediction Index software. Notably, the company plans a targeted launch of the product in the United States.
The market is also upbeat about Edwards Lifesciences’ recent CE Mark for its self-expanding CENTERA valve. The regulatory approval is likely to boost the company's Transcatheter Heart Valves segment.
Management continues to anticipate CE Mark enrollment for CardiAQ valve by 2019. In this regard, the company has already begun treating patients in the CE Mark trial called CLASP for PASCAL transcatheter mitral repair program.
Solid Guidance
Edwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected $3.5-$3.9 billion range. Adjusted EPS expectations have also been lifted to $4.43-$4.63 from the earlier $4.10-$4.30.
Product Pipeline Development
We are encouraged by Edwards Lifesciences’ focus on building its pipeline that should further strengthen its foothold across all its operating businesses. The company also witnessed growth across its emerging portfolio of mitral and tricuspid repair therapies.
Edwards Lifesciences’ new Ultra System, including an on-balloon delivery system and next-generation sheath technology, is expected to be available in the United States and in Europe in late 2018.
Other Key Picks
A few other top-ranked stocks in the broader medicalsector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank of 2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
3 Reasons Why You Should Invest in Edwards Lifesciences Now
Edwards Lifesciences Corporation (EW - Free Report) has been on a healthy growth trajectory of late. Positive tidings on the regulatory front have been lending the company a competitive edge in MedTech. With solid prospects, this Zacks Rank #2 (Buy) stock is an attractive pick at the moment.
Edwards Lifesciences has outperformed the broader industry over the last three months. The stock has gained 19.6%, ahead of the S&P 500’s decline of 3.8% and the industry’s 5.2%.
The stock has a market cap of $24.19 billion. The company’s five-year historical growth rate is also favorable at 23.4% compared with the 10.2% increase of its industry and the S&P 500’s 2.8% gain.
The company has a positive earnings surprise of 9.9% for the last four quarters. Also, it has a long-term expected earnings growth rate of 15.1%.
Headquartered in Irvine, CA, the company’s estimate revision trend for the current year has been positive. In the past couple of months, 12 analysts moved north, with no movement in the opposite direction. Earnings estimates rose around 8.7% to $4.52 per share over the same time frame.
Let’s find out whether the recent positive trend is a sustainable one.
Favorable Regulatory Tidings
In a bid to strengthen its position in predictive analytics, Edwards Lifesciences recently announced the approval of De Novo request from the FDA for the Acumen Hypotension Prediction Index software. Notably, the company plans a targeted launch of the product in the United States.
The market is also upbeat about Edwards Lifesciences’ recent CE Mark for its self-expanding CENTERA valve. The regulatory approval is likely to boost the company's Transcatheter Heart Valves segment.
Management continues to anticipate CE Mark enrollment for CardiAQ valve by 2019. In this regard, the company has already begun treating patients in the CE Mark trial called CLASP for PASCAL transcatheter mitral repair program.
Solid Guidance
Edwards Lifesciences has raised its 2018 sales expectations to the high end of the previously projected $3.5-$3.9 billion range. Adjusted EPS expectations have also been lifted to $4.43-$4.63 from the earlier $4.10-$4.30.
Product Pipeline Development
We are encouraged by Edwards Lifesciences’ focus on building its pipeline that should further strengthen its foothold across all its operating businesses. The company also witnessed growth across its emerging portfolio of mitral and tricuspid repair therapies.
Edwards Lifesciences’ new Ultra System, including an on-balloon delivery system and next-generation sheath technology, is expected to be available in the United States and in Europe in late 2018.
Other Key Picks
A few other top-ranked stocks in the broader medicalsector are Bio-Rad Laboratories (BIO - Free Report) , athenahealth, Inc. and Varian Medical Systems, Inc. .
Bio-Rad Laboratories sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 20%.
athenahealth is a Zacks #1 Ranked player. The company has a long-term expected earnings growth rate of 21.5%.
Varian Medical has a long-term expected earnings growth rate of 8%. The stock carries a Zacks Rank of 2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>